Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05813665 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

StatusNot Yet Recruiting
PhasePhase 3
Started2023-04
View on ClinicalTrials.gov ↗

Amendment history

2023-04-16
Study Status, Outcome Measures v1
Secondary endpointsdetails revised at 2 of 11 entries
2023-04-03
Original filing
This is a phase Ⅲ, multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of narlumosbart (JMT103) in patients with unresectable or surgically difficult giant cell tumor of bone (GCTB). This clinical trial study hypothesizes narlumosbart administration groups are not inferior to active control administration groups.
Trial Details
NCT Number NCT05813665
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Giant Cell Tumor of Bone
Enrollment 146 participants
Start Date 2023-04
Primary Completion 2028-06 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2023-04-19